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Abstract
We derive the sample size formulae for comparing two negative binomial rates based on both the relative and absolute
rate difference metrics in noninferiority and equivalence trials with unequal follow-up times, and establish an approximate
relationship between the sample sizes required for the treatment comparison based on the two treatment effect metrics. The
proposed method allows the dispersion parameter to vary by treatment groups. The accuracy of these methods is assessed
by simulations. It is demonstrated that ignoring the between-subject variation in the follow-up time by setting the follow-up
time for all individuals to be the mean follow-up time may greatly underestimate the required size, resulting in underpowered
studies. Methods are provided for back-calculating the dispersion parameter based on the published summary results.
Keywords: Fixed margin approach; Mixed Poisson distribution; Negative binomial distribution; Noninferiority margin; Overdis-
persion; Unequal follow-up
1 Introduction
Many clinical trials involve comparing the rate of events that may occur more than once in individual patients. Examples include
exacerbations in chronic obstructive pulmonary disease, relapses in multiple sclerosis, tumor recurrence in bladder cancer,
seizures in epileptics, and hospitalizations. When the event counts are analyzed using Poisson regression, the observed variance
is often larger than expected (Glynn and Buring, 1996; Wang et al., 2009), and this phenomenon is called overdispersion. The
quasi-Poisson approach (i.e. Poisson regression with overdispersion adjustment), which simply inflates the variance obtained
from the Poisson regression by a constant factor, may not be able to control the type I error well when there is a large variation
in the follow-up time (Tang, 2015). This will be further illustrated by simulation, and a theoretical justification will be provided
in Appendix A.3. Negative binomial (NB) regression has been widely used to analyze recurrent events in recent years because
it provides a convenient way to account for the overdispersion exhibited in the recurrent event data.
The noninferiority (NI) trials, commonly used in the drug development, show that a new treatment is not materially less
efficacious than a standard control treatment, or more precisely that the new product is not worse than the active control by
a pre-specified small amount called NI margin (EMA-CHMP, 2005; US-FDA, 2010). The NI trial design is chosen if it would
be unethical to run a placebo controlled trial or because the new treatment may offer important advantages over the standard
treatment in terms of convenience of administration, improved safety, reduced cost, or better compliance (Hung et al., 2007;
Hahn, 2012).
In equivalence trials, the objective is to demonstrate that the test product is not clinically different from a standard control
treatment (Liao, 2015; Alten and Cronstein, 2015). Equivalence trials are often used in the development of the biosimilar
product, which is a biological product that is highly similar to the reference product notwithstanding minor differences in
clinically inactive components (US-FDA, 2012).
Sample size formulae have been developed for NI and equivalence trials comparing rates of recurrent events by Cook et al.
(2007) and Zhu (2017). Both approaches use the approximation by setting the follow-up time for all patients to be the mean
follow-up time. Tang (2015) demonstrated both theoretically and numerically that ignoring the between-subject variation in
the follow-up time leads to underpowered studies in superiority trials. We will show that the same conclusion holds for NI
and equivalence trials. In addition, Cook et al. (2007) did not assume the margin is fixed in the power calculation, and the
interpretation of the P -value or type I error can be quite different in the sense that it requires the assumption that both
the historical and NI trials can be repeated infinitely many times (Hung et al., 2003, 2007). The recent regulatory guidelines
(EMA-CHMP, 2005; US-FDA, 2010) recommend the fixed margin approach.
In this paper, we extend Tang (2015) sample size calculation method for comparing two NB rates in superiority trials with
unequal follow-up times to NI and equivalence trials. We compare the treatments on basis of both the absolute and relative
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rate difference metrics, and establish an approximate relationship between the required sample sizes on the two metrics. The
absolute rate difference metric was not studied by Tang (2015). We derive the power and sample size formulae for NI trials
in Section 2, and for equivalence trials in Section 3. The proposed methods are assessed via simulation and compared with
Zhu (2017) approach for two types of clinical trial designs. In one design, the planned treatment duration is the same for all
subjects. In the second design, subjects are enrolled at different calendar times, but administratively censored at the same
calendar time. In Appendix A.1, we derive analytic expression for calculating the mean and variance of the follow-up time
in the two designs. We also extend the methodology by allowing the dispersion parameters to differ by treatment groups.
The sample size determination requires information about the dispersion parameter κ, which is rarely reported in the medical
literature. In Appendix A.2, we describe methods for back-calculating κ from published summary results.
2 Sample size for NI trials
The NB distribution is the probability distribution of the number of failures Y before κ−1 successes in a series of independent
Bernoulli trials with the same probability p of success
Pr(Y = y) =
Γ(y + 1/κ)
y! Γ(1/κ)
p1/κ(1− p)y. (1)
For the analysis of overdispersed count data, it is convenient to use the parametrization: µ = (1− p)/(κp) is the mean, and κ
is the dispersion parameter. Note that p = 1/(κµ+ 1). The NB distribution can be derived as a gamma mixture of Poisson
distribution. If Y is Poisson distributed with mean εµ, and ε is gamma distributed with mean 1 and variance κ, the marginal
distribution of Y is a NB distribution, and we will denote it by Y ∼ NB(µ, κ). This representation does not require κ−1 to be an
integer. The random effect ε can also be modeled by other distributions such as the log-normal or inverse Gaussian distributions,
but the gamma mixing distribution is the most commonly used because the resulting marginal distribution has a closed-form
expression (Lawless, 1987). The random effect ε captures the between-subject heterogeneity in event rates, and κ measures the
degree of heterogeneity. Including important risk factors in the model may reduce heterogeneity. The NB distribution tends
to fit the overdispersed count data better than the Poisson distribution (Glynn and Buring, 1996; Wang et al., 2009), and its
mean µ is always less than its variance µ+ κµ2 (Tang, 2015).
Suppose in a trial, n subjects are randomized to receive an active (g = 1) or control (g = 0) treatment. Let tgj denote the
follow-up time and ygj the number of observed events for subject j = 1, . . . , ng in treatment group g. We assume that the
event rate λg = exp(γg) in each treatment group is constant over time, and ygj ∼ NB(λgtgj , κ). The log-likelihood function
can be written as
ℓ =
1∑
g=0
ng∑
j=1
[
log
Γ(ygj + 1/κ)
Γ(1/κ)
+ ygj log(κλgtgj)− (ygj + κ−1) log(1 + κλgtgj)
]
. (2)
Based on the analytic result of Lawless (1987), Tang (2015) showed that the maximum likelihood estimates (MLE) γˆ0, γˆ1 and
κˆ are asymptotically independent, and the variance of the log-relative risk estimate βˆ = log(λˆ1/λˆ0) = γˆ1− γˆ0 derived from the
expected Fisher information matrix is given by
var(γˆg) =
 ng∑
j=1
λgtgj
1 + κλgtgj
−1 ≈ 1
npgdg
and var(βˆ) =
1∑
g=0
var(γˆg) ≈ 1
n
[
1
d0p0
+
1
d1p1
]
, (3)
where dg = E[λgtgj/(1+ κλgtgj)], and pg = ng/n is the proportion of subjects randomized to treatment group g. The variance
of βˆ can also be obtained from the observed information matrix. The two variance estimates are asymptotically equivalent.
The 100(1− α)% confidence interval (CI) is
[cl, cu] = [βˆ − z1−α/2
√
v̂ar(βˆ), βˆ + z1−α/2
√
v̂ar(βˆ)]
for β, and [exp(cl), exp(cu)] for the event rate ratio λ1/λ0, where v̂ar(·) is the variance estimated at the MLE, and zp is the
pth percentile of the standard normal distribution N(0, 1).
2.1 Sample size for the rate ratio effect measure
Suppose a lower event rate is desirable. In the NI trial, the objective is to demonstrate that the experimental treatment is no
worse than the active comparator by Mr0, where Mr0 > 1 is the pre-specified NI margin on the rate ratio. The hypothesis can
be expressed as
H0 :
λ1
λ0
≥Mr0 vs H1 : λ1
λ0
< Mr0.
The margin Mr0 is generally chosen to be close to 1 in order to demonstrate that the new treatment is not materially inferior
to the active comparator. Please refer to US-FDA (2010), EMA-CHMP (2005) and Hung et al. (2003) for more details on the
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specification and interpretation of the NI margin. In the fixed margin approach, we compare the upper limit of the CI for
λ1/λ0 with Mr0. The noninferiority of the experimental treatment to the active comparator can be claimed if exp(cu) < Mr0
or equivalently if cu = βˆ + z1−α/2
√
v̂ar(βˆ) < log(Mr0). The power of the test is
P = Pr(βˆ + z1−α/2
√
v̂ar(βˆ) < log(Mr0)) = Pr
Z < −z1−α/2
√
v̂ar(βˆ)− β + log(Mr0)√
var(βˆ)
 ,
which can be expressed as
P ≈ Φ
( √
n|β∗|√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
= Φ
(√
n| log(Mr0)− log(λ1λ0 )|√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
, (4)
where β∗ = log(Mr0λ0/λ1) and Z = (βˆ − β)/
√
var(βˆ) is asymptotically distributed as N(0, 1). Equation (4) is also valid if
Mr0 < 1, and the objective is to demonstrate that the event rate in the experimental arm is not materially lower than the
control rate. Inverting (4) yields the total sample size
nr =
[
1
d0p0
+
1
d1p1
]
f, (5)
where f = (z1−α/2 + zP )
2/β∗
2
. The formula of Friede and Schmidli (2010) is a special case of (5) when all subjects have
the same follow-up time. When Mr0 = 1, (5) reduces to the sample size formula of Tang (2015) for superiority trials. The
superiority and NI trials differ in the assumption on the relative efficacy of the two treatments. In superiority trials, λ1/λ0 is
expected to be far below 1. In NI trials, the active and control treatments are expected to have similar effects (i.e. λ1/λ0 ≈ 1).
The sample size for NI trials can be determined by adapting the formulae for superiority trials (Friede and Schmidli, 2010)
with β∗2 = log2(Mr0λ0/λ1) replacing β
2 = log2(λ0/λ1). In this approach, d0, d1 and the variance of the treatment effect are
still calculated based on the true event rates. One shall be cautious in using this adapted approach by avoiding the possibility
of modifying the true rate as λ1 = exp(β
∗)λ0. Such a mistake was made in Zhu (2017), leading him to express concerns about
the inaccuracy of this adapted approach. Let take the case reported on row 8, table 5 in the supplementary material of Zhu
(2017) as an example. Suppose κ = 0.5, λ0 = λ1 = 1, tgj ≡ 1 (no dropout), p0 = p1 = 1/2, andMr0 = 1.3. By (5), 686 subjects
(343 per arm) are needed to achieve a power of P = 80% at α = 0.05. The power estimated from 40, 000 simulated trials is
80.43%. Zhu (2017) got a size estimate of 314 subjects per group using method 3 of Zhu and Lakkis (2014) for superiority trials
by replacing exp(β) by Mr0 (i.e. β
∗ = log(Mr0) since λ0 = λ1). Zhu (2017) estimate was wrong because the true rates were
implicitly modified as (λ0, λ1) = (1, 1.3) in his calculation. The resulting size is also 343 subjects per arm if Zhu and Lakkis
(2014) formula for superiority trials is appropriately applied. The simulation studies in both Friede and Schmidli (2010) and
this paper demonstrate the accuracy of (5) or equivalently the adapted method in moderate to large samples.
Tang (2015) derived the lower and upper bounds for dg
dgl =
λgν
2
tg
νtg + κλgE(t
2
gj)
≤ dg ≤ dgu =
λgνtg
1 + κλgνtg
, (6)
where νtg = E(tgj) is the mean follow-up time in group g. Replacing dg by dgu and dgl in (5) yields respectively the lower and
upper bounds for nr. Similar bounds on the power can be obtained by replacing dg by dgl and dgu in (4).
The lower size bound is the required size when all subjects in treatment group g are followed for the same time tgj = νtg ,
and can be decomposed into two terms
nrl =
[
1
p0λ0νt0
+
1
p1λ1νt1
]
f +
(
1
p0
+
1
p1
)
κ f. (7)
The first term is the required size ignoring overdispersion (i.e. the count data follow Poisson distribution), and the second
term corrects for overdispersion. In the upper size bound, another term is added to account for variation in the duration of
the follow-up
nru = nrl + κf
[
1
p0
CV20 +
1
p1
CV21
]
, (8)
where CVg =
√
var(tgj)/νtgj is the coefficient of variation for tgj . Note that nru can be bounded by
nru ≤ n˜ru = nrl + κf [ tm0 − νt0
νt0
+
tm1 − νt1
νt1
],
where tmg is the maximum follow-up time in treatment group g.
The power and sample size calculation requires dg, νtg = E(tgj), E(t
2
gj), and the corresponding analytic formulae are given
in Appendix A.1 for two types of designs considered in Section 2.3.1. The estimate of the dispersion parameter κ is rarely
reported in the medical literature. Appendix A.2 illustrates how to use (6) to back-calculate κ from the summary results on
the event rate and rate ratio.
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2.2 Sample size for the absolute rate difference measure
Now suppose we want to compare the treatments based on the absolute rate difference measure. The objective is to show that
the active rate is no worse than the control rate by Md0, where Md0 is the NI margin on the absolute rate difference metric.
The hypothesis can be expressed as
H0 : λd = λ1 − λ0 ≥Md0 vs H1 : λd < Md0.
The variance of λˆd = λˆ1 − λˆ0 = exp(γˆ1)− exp(γˆ0) can be derived from (3) via the delta method
var(λˆg) = λ
2
gvar(γˆg) and var(λˆd) =
1∑
g=0
var(λˆg) =
1
n
[
λ20
d0p0
+
λ21
d1p1
]
.
The 100(1− α)% CI for λˆd is
[cld , cud ] = [λˆd − z1−α/2
√
v̂ar(λˆd), λˆd + z1−α/2
√
v̂ar(λˆd)].
The noninferiority can be claimed if cud < Md0. The power of the test is
P = Pr(cud < Md0) = Pr
 λˆd − λd√
var(λˆd)
<
Md0 − λd − z1−α/2
√
v̂ar(λˆd)√
var(λˆd)
 ,
which can be written as
P = Φ
√n|Md0 + λ0 − λ1|√
λ2
0
d0p0
+
λ2
1
d1p1
− z1−α/2
 . (9)
Equation (9) is also valid if Md0 < 0 and the objective is to demonstrate that the event rate in the experimental arm is not
materially lower than that in the control arm. Inverting (9) yields the sample size
nd =
(
λ20
p0d0
+
λ21
p1d1
)
(z1−α/2 + zP )
2
(Md0 + λ0 − λ1)2 . (10)
When Md0 = 0, (10) reduces to the sample size formula for testing the absolute rate difference in superiority trials. Replacing
dg by dgu and dgl in (10) yields respectively the lower ndl and upper ndu bounds for nd.
In Appendix A.4, we show that (5) and (10) generally produce similar sample size estimate if the effects of the two treatments
do not differ too much, and
Md0 = λ¯ log(Mr0). (11)
where λ¯ =
√
λ0λ1 = λ0 exp(β/2) is the geometric mean of λ0 and λ1.
2.3 Numerical Examples
2.3.1 Assessment of type I error rate
We perform simulations to assess the type I error of the Wald-CI-based approach in the NB regression and quasi-Poisson
regression with overdispersion adjustment. Two types of designs are considered. In design 1, the planned treatment duration
is τc years for all patients, and the loss to follow-up is assumed to be exponentially distributed with mean δ
−1 years, and
independent of the recurrent event process. In design 2, we assume patients are enrolled during an accrual period of τa years,
and followed for an additional τc years after the closure of recruitment (Cook, 1995). The patient entry time egj is distributed
with density function
g(egj) =
η exp(−ηegj)
1− exp(−ητa) , 0 ≤ egj ≤ τa, (12)
given by Lachin and Foulkes (1986). The entry distribution is convex (faster patient entry at the beginning) if η > 0, and
concave (lagging patient entry) if η < 0, and uniform g(egj) = 1/τa if η → 0. We assume uniform entry in the simulation. The
loss to follow-up distribution is the same as design 1. Since all subjects will be administratively censored at time τ = τa + τc,
but enter the study at different time, there is greater between-subject variation in the follow-up time in design 2 than in design
1. Appendix A.1 provides analytic formulae for calculating dg, νtg = E(tgj) and E(t
2
gj) for the two designs.
In design 1, we assume τc = 2 years, and the overall dropout rate at year 2 is 25% (δ = 0.1438). In design 2, we fix τa = τc = 2
years, and the loss to follow-up is exponentially distributed with mean 1/δ = 5 years. In both designs, we set (λ0, κ) = (0.6, 1) or
(0.9, 1.5), andMr0 = 1.2 or 1.3. Equal treatment allocation (p0 = p1 = 1/2) is assumed in the simulation. For the test based on
the rate ratio effect metric, we assume λ1 = λ0Mr0 in simulating the data, and the total sample size is estimated using (5) at the
target P = 80% power and a two-sided α = 0.05 significance level under the assumption exp(β) = λ1/λ0 = 0.65, 0.8, 0.9, 1, 1.05.
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For the test of the absolute rate difference, we set λ1 = λ0+Md0 in simulating the data, and the sample size is determined by (10)
at P = 80% and α = 0.05 under the assumption exp(β) = λ1/λ0 = 0.65, 0.8, 0.9, 1, 1.05, where Md0 = λ0 exp(β/2) log(Mr0).
We do not consider the case when exp(β) > 1.05 partially because the resulting sample size could too large to be of practical
interest, and partially because the performance of the NB regression is expected to become better as the sample size increases.
In all cases, 10, 000 trials are simulated, and there is > 95% chance that the empirical one-sided type I error estimate (its
standard error is about
√
0.025 ∗ 0.975/10000≈ 0.16%) is within 0.32% of the true error rate.
The results are reported in table 1 and 2 respectively for design 1 and 2. The test based on the rate ratio metric generally
provides a better type I error control than the test of the absolute rate difference. For the NB regression, the empirical estimate
of the one-sided type I error is generally close to the nominal 0.025 level. In the worst case, the empirical type I error estimate
reaches 2.81% for the test based on the rate ratio, and 2.97% for the test based on the absolute rate difference.
The quasi-Poisson regression provides quite poor control of the type I error in NI trials, and similar phenomenon was observed
in superiority trials (Tang, 2015). In NI trials, the empirical one-sided type I error estimate is in the 3.0 − 4.0% range for all
cases in design 2 because of the large variation in the follow-up time, and above 2.80% in most cases for design 1. In Appendix
A.3, we show that the variance of the treatment effect estimate is underestimated under H0 in the quasi-Poisson regression if
there is a large variation in tgj ’s, and this explains why the type I error is inflated in this approach.
2.3.2 Assessment of power and sample size
The set up for assessing the performance of the power and sample size formulae is similar to that for the type I error assessment
except that we assume λ1 = λ0 exp(β) in simulating data for both tests based on the relative and absolute rate difference, and
the two margins satisfy Md0 =
√
λ0λ1 log(Mr0). Since the quasi-Poisson regression could not control the type I error well, its
performance on power will not be assessed. We will compare (5) with Zhu (2017) method. In the latter approach, the follow-up
time for all individuals is set to be the mean follow-up time,
nzr =
[
z1−α/2
√
V˜0 + zP
√
V1
]2
log2(Mr0λ0/λ1)
, (13)
where νt = νt0 = νt1 , V1 = (p
−1
0 + p
−1
1 )κ+ (p0λ0νt)
−1 + (p1λ1νt)
−1, V˜0 = (p
−1
0 + p
−1
1 )κ+ (p0λ˜0νt)
−1 + (p1λ˜1νt)
−1, θ = p1/p0,
a = −κνtMr0(1 + θ), b = κνt(λ0Mr0 + θλ1)− (1 + θMr0), c = λ0 + θλ1, and λ˜0 = (−b−
√
b2 − 4ac)/(2a) and λ˜1 =Mr0λ˜0 are
the approximate MLE under H0 : λ1 =Mr0λ0.
The results are reported in table 3 and 4 respectively for design 1 and 2. As expected, the estimated size nd for the test of
the rate difference is generally close to the size nr for the test based on the rate ratio especially when exp(β) = λ1/λ0 is near
1. If the experimental treatment is much more effective than the control treatment, nd tends to be slightly larger than nr. For
the test based on the rate ratio effect metric, the simulated power (SIM) at nr is within 1% of the nominal power in nearly all
cases for both designs.
We evaluate the power of the test of the absolute rate difference at both nd and nr. The SIM at nd is generally close to the
targeted 80% level, and the power approximation slightly deteriorates when the experimental treatment is much more effective
than the active control (i.e. exp(β) = λ1/λ0 = 0.65 and 0.8), and the SIM deviates from the nominal level by 2.48% in the
worst case. The SIM at nr is closer to the targeted level than the SIM at nd when exp(β) = λ1/λ0 = 0.65 and 0.8. This
suggests that the sample size for the test of the absolute rate difference can be calculated based on either (10) or (5) by setting
Mr0 = exp(Md0/λ¯), and the latter approach may be preferred.
Zhu (2017) estimate nzr given in (13) is generally close to the lower size bound nrl, and nzr < nrl when the experimental
treatment is much more effective than the active control (exp(β) = λ1/λ0 is far below 1). The use of the lower size bound
nrl or Zhu’s estimate nzr by ignoring the variability in the duration of the follow-up underestimates the required size, and the
amount of underestimation ranges from 3 − 6% for design 1, and 7 − 10% for design 2. The upper size bounds overestimate
the sample size by 1− 2.5% in design 1, and by 3− 9% in design 2.
2.4 Extension to dispersion parameter heterogeneity
So far we assume a common dispersion parameter κ across treatment groups. In practice, the dispersion parameter could differ
by treatments. If the assumption of a common dispersion parameter is relaxed in the analysis, the corresponding power and
sample size formulae remain almost unchanged except that one needs to replace κ in dg, dgu and dgl by the treatment specific
dispersion parameter κg. This modification is also suitable for superiority trials (Tang, 2015) since superiority trials can be
viewed as the special cases of NI trials when Mr0 = 1 and Md0 = 0.
We perform a small simulation study to assess the accuracy of the power and sample size formulae under heterogeneous
dispersion. Only design 1 is considered, where τc = 2, p0 = p1 = 1/2, and the overall dropout rate is 25% (δ = 0.1438).
We set λ0 = 0.6 or 1, exp(β) = λ1/λ0 = 0.8, 0.9 or 1, (κ0, κ1) = (2, 1), (1, 2), (2, 0.5) or (0.5, 2), Mr0 = 1.2 or 1.3, and
Md0 =
√
λ0λ1 log(Mr0).
In the analysis of simulated data, we fit a separate NB regression for each treatment group, and calculate the test statistic
based on the analytic formula. This analysis strategy works if the model does not include other covariates except the treatment
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status. The results at Mr0 = 1.3 are displayed in Table 5. The performance at Mr0 = 1.2 is similar, and hence omitted. For
the test based on the event rate ratio, the SIM at nr is generally close to the 80% nominal level. The power approximation for
the test based on the absolute difference may slightly deteriorate, and the SIM at nd can be off the targeted power by about
4%. Again, the results indicate that it might be better to use (5) to calculate the sample size for the test of the absolute rate
difference by setting Mr0 = exp(Md0/λ¯).
3 Sample size for equivalence trials
3.1 Sample size for the rate ratio effect measure
The purpose of an equivalence trial is to demonstrate that the test product is neither superior nor inferior to the reference
product. The hypothesis can be written as
H0 :
λ1
λ0
≤Mrl or λ1
λ0
≥Mru vs H1 : Mrl < λ1
λ0
< Mru,
where Mrl < 1 and Mru > 1 are the pre-specified lower and upper equivalence boundaries on the rate ratio.
The two treatments are not clinically different if the whole CI of exp(β) = λ1/λ0 lies completely within [Mrl,Mru], or
equivalently if the whole CI of β falls completely within [log(Mrl), log(Mru)]. The power is
P = Pr(βˆ + z1−α/2
√
v̂ar(βˆ) < log(Mru) and βˆ − z1−α/2
√
v̂ar(βˆ) > log(Mrl))
= Pr
z1−α/2
√
v̂ar(βˆ)− β + log(Mrl)√
var(βˆ)
< Z <
−z1−α/2
√
v̂ar(βˆ)− β + log(Mru)√
var(βˆ)

≈ max
{
Φ
( √
n log(Mruλ0/λ1)√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
− Φ
( √
n log(Mrlλ0/λ1)√
(d0p0)−1 + (d1p1)−1
+ z1−α/2
)
, 0
}
.
(14)
There is no closed-form sample size formula except in few special cases. When log(Mruλ0/λ1) = − log(Mrlλ0/λ1), the sample
size is given by
n =
[
1
d0p0
+
1
d1p1
]
(z1−α/2 + z(1+P )/2)
2
log2(Mruλ0/λ1)
=
[
1
d0p0
+
1
d1p1
]
(zα/2 + z(1−P )/2)
2
log2(Mruλ0/λ1)
. (15)
Let ∆min = min[log(Mruλ0/λ1),− log(Mrlλ0/λ1)] and ∆max = max[log(Mruλ0/λ1),− log(Mrlλ0/λ1)]. In Appendix A.4, we
show that the sample size is bounded by[
1
d0p0
+
1
d1p1
]
(z1−α/2 + z(1+P )/2)
2
∆2max
≤ n ≤
[
1
d0p0
+
1
d1p1
]
(z1−α/2 + z(1+P )/2)
2
∆2min
. (16)
The sample size can be approximated by the upper bound in (16) if ∆min is sufficiently close to ∆max.
When Mrlλ0/λ1 is sufficiently smaller than 1, (28) can be approximated by (Chow and Wang, 2001; Chow et al., 2008)
P ≈ Φ
( √
n log(Mruλ0/λ1)√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
and the sample size can be approximated by the size for a NI trial with margin Mr0 = Mru
n ≈
[
1
d0p0
+
1
d1p1
]
(z1−α/2 + zP )
2
log2(Mruλ0/λ1)
.
Similar approximation may be obtained when Mruλ0/λ1 is sufficiently larger than 1.
In general, sample size may be obtained by inverting (28) numerically (e.g. bisection method), which is the smallest integer
at which the power in (28) is not less than the target power.
3.2 Sample size for the absolute rate difference measure
On the absolute rate difference metric, the hypothesis is
H0 : λd = λ1 − λ0 ≤Mdl or λd ≥Mdu vs H1 :Mdl < λd < Mdu,
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where Mdl < 0 and Mdu > 0 are the pre-specified lower and upper equivalence boundaries on the absolute rate difference
metric. We can derive the power
P = Pr(cld > Mdl and cud < Mdu)
= Pr
Mdl − λd + z1−α/2
√
v̂ar(λˆd)√
var(λˆd)
<
λˆd − λd√
var(λˆd)
<
Mdu − λd − z1−α/2
√
v̂ar(λˆd)√
var(λˆd)

≈ max
Φ
√n(Mdu + λ0 − λ1)√
λ2
0
d0p0
+
λ2
1
d1p1
− z1−α/2
− Φ
√n(Mdl + λ0 − λ1)√
λ2
0
d0p0
+
λ2
1
d1p1
+ z1−α/2
 , 0
 .
(17)
Sample size can be calculated by numerically inverting (17). In the special case when Mdu + λ0 − λ1 = −(Mdl + λ0 − λ1), we
have
n =
[
λ20
p0d0
+
λ21
p1d1
]
(z1−α/2 + z(1+P )/2)
2
(Mdu + λ0 − λ1)2 .
When the effects of the two treatments do not differ too much, and the margins satisfy Mdl = λ¯ log(Mrl) and Mdu =
λ¯ log(Mru), the power estimates based on rate ratio metric (i.e. via (28)) and the absolute rate difference metric (i.e. via (17))
are close, and therefore the corresponding sample size estimates are close. The proof is similar to that for (11).
As in Section 2, replacing dg by dgl or dgu in the power formulae for tests based on both the absolute and relative rate
difference metrics yields the lower and upper power bounds. The sample size bounds can be obtained by numerically inverting
the power bounds. If the dispersion parameter differs by treatment, the corresponding power and sample size formulae remain
almost unchanged except that one needs to replace κ in dg, dgu and dgl by the treatment specific dispersion parameter κg.
3.3 Numerical examples
We perform a small simulation study to assess the accuracy of the power and sample size formulae for equivalence trials. We fix
τc = 2 years in design 1, and τa = τc = 2 years in design 2. The distribution of the loss to follow-up time is the same as that in
simulation 1 in Section 2.3.1. In both designs, we set (λ0, κ) = (0.6, 1) or (0.9, 1.5) and exp(β) = λ1/λ0 = 1 or 1.05. We choose
the margin as Mru = 1/Mrl = 1.3 on the rate ratio metric, and Mdu = −Mdl =
√
λ0λ1 log(Mru) = λ0 exp(β/2) log(Mru) on
the absolute rate difference metric.
The simulated powers are within 1% of the nominal level for tests based on both absolute and relative rate difference metrics
in all cases. The use of the lower size bound nrl or Zhu’s estimate nzr by ignoring the variability in the duration of the follow-up
underestimates the required size, and the degree of underestimation is similar to that for NI trials reported in Section 2.3.2.
The equivalence trial often requires larger sample size than a NI trial (Liao, 2015). Below is an example. At (λ0, λ1/λ0, κ) =
(0.6, 1, 1) in design 1, it needs 928 subjects (reported in Table 3) to demonstrate with 80% power that the test treatment is
not inferior to the reference product at a margin of Mr0 = 1.3 on the rate ratio metric, while 1242 subjects are required to
show that the test product is neither inferior nor superior to the reference product at the margin of Mru = 1/Mrl = 1.3. The
equivalence trial requires 1242/928− 1 = 33.8% more subjects than the NI trial. The difference in sample sizes between the
NI and equivalence trials becomes smaller (1384 vs 1435 subjects) at (λ0, λ1/λ0, κ) = (0.6, 1.05, 1), and becomes larger (668 vs
1469 subjects) at (λ0, λ1/λ0, κ) = (0.6, 0.952, 1).
We also conduct a simulation study to assess the type I error of the equivalence tests. The empirical type I error is generally
close to the nominal level. The result is not reported due to limited space.
4 Discussion
We derive the power and sample size formulae for comparing two NB rates based on the absolute and relative rate difference
in NI and equivalence trials. The sample size formula for superiority trials can be viewed as a special case of the formula
for NI trials by setting Mr0 = 1 and Md0 = 0. The assumption of a common dispersion parameter across treatments can be
relaxed. The accuracy of the proposed methods is demonstrated by simulations in moderate to large samples. We show that
the sample size in NI and equivalence trials will be underestimated if one ignores the variation in the follow-up time by setting
the follow-up time for all individuals to be the mean follow-up time and estimates the sample size using either the lower size
bound or Zhu (2017) approach. The degree of underestimation can be substantial if the follow-up time varies greatly across
patients. The result is consistent with that for superiority trials (Tang, 2015, 2017). We also provide theoretical justification
why the quasi-Poisson regression provides quite poor control of the type I error in case of unequal follow-up, which is confirmed
by simulation.
It can be challenging to specify parameters such as the event rate in the control arm and the dispersion parameter κ at the
design stage of a trial. In particular, the estimate of κ is generally not directly reported in the medical literature. Appendix
A.2 describes two potential ways to back-calculate κ based on the published point estimates of the event rates and rate ratio.
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In practice, one may also perform interim analyses of blinded data to re-estimate these nuisance parameters and revise the
sample size during the mid-course of the trial (Friede and Schmidli, 2010; Tang, 2015), in which the two treatments are typically
assumed to be equally effective (i.e. λ1 = λ0) in estimating the nuisance parameters.
The proposed formulae are derived based on the Wald CI from the NB regression. They may not be suitable for small trials.
Aban et al. (2009) demonstrated via simulations that the type I error of the Wald test may be inflated if the trial size is below
50 patients per arm. However, this may not be a particular concern in NI and equivalence trials since the sample size in a NI or
equivalence trial is usually large. The inflation of the type I error is partially because the MLE of κ tends to be biased toward
0 (Saha and Paul, 2005) since there is no adjustment for the loss of degrees of freedom in estimating the covariate effects in the
MLE procedure. This is analogous to the traditional analysis of variance. In small samples, we can employ some techniques
to reduce the bias in the parameter estimation, or use more robust tests for treatment comparison. Further research will be
performed for the analysis of small trials.
A Appendix
A.1 Estimation of dg, E(tgj) and E(t
2
gj) in two designs
We derive expressions for dg, E(tgj) and E(t
2
gj). Note that dg is required for computing nr and nd, and νtg = E(tgj) and E(t
2
gj)
are needed in calculating the sample size bounds. We caluate dgu and dgl based on (6). Replacing dg by dgu and dgl in power
and sample size formulae yields the corresponding bounds.
In design 1, all subjects will be followed for τc years, but may discontinue with exponential loss to follow-up (mean δ
−1
years). Tang (2015) showed that when δ 6= 0, the overall dropout rate is wc = 1− exp(−δτc), and
dg = E
[
λgtgj
1 + κλgtgj
]
=
1
κ
− exp(−δτc)
κ+ κ2λgτc
−
∫ τc
0
δ exp(−δt)
κ+ κ2λgt
dt =
∫ τc
0
λg exp(−δt)
(1 + κλgt)2
dt,
E(tgj) =
1− exp(−δτc)
δ
=
wc
δ
,
E(t2gj) =
2[1− (1 + δτc) exp(−δτc)]
δ2
.
(18)
If there is no dropout (i.e. δ = 0), then dg = dgl = dgu =
λgτc
1+κλgτc
, E(tgj) = τc and E(t
2
gj) = τ
2
c .
In design 2, subjects are enrolled during an accrual period of τa years, and followed for an additional τc years after the
closure of recruitment. The loss to follow-up distribution is the same as design 1. The entry time distribution of egj is given
in (12). When δ 6= 0 and η 6= 0, we get by the double expectation formula
E(tgj) = E[E(tgj |egj)] = 1
δ
− exp(−δτc)
δ
h1,
E(t2gj) =
2
δ2
{1− exp(−δτc)[(δτc + 1)h1 + δh2]} ,
dg =
1
κ
−
∫ τc
0
δ exp(−δt)
κ+ κ2λgt
dt−
∫ τa
0
exp(−δg(t+ τc))
κ+ κ2λ(t+ τc)
h(t)dt =
∫ τc+τa
0
λgπ(t)
(1 + κλgt)2
dt,
(19)
where τ = τa + τc, π(t) = exp(−δt) if t ≤ τc, π(t) = exp(−δt)1−exp[−η(τ−t)]1−exp[−ητa] if t > τc, and
h(t) =
δ + (η − δ) exp(η(t− τa))
1− exp(−ητa) =
δ[1− exp(−η(τa − t))] + η exp[−η(τa − t)]
1− exp(−ητa) ,
h1 =
η
η − δ
exp(−δτa)− exp(−ητa)
1− exp(−ητa) =
η exp(−ητa)
1− exp(−ητa)
1− exp[−(δ − η)τa]
δ − η ,
h2 =
η exp(−ητa)
1− exp(−ητa)
1− [(δ − η)τa + 1] exp[−(δ − η)τa]
(δ − η)2 .
(20)
When η = δ, h1 and h2 are replaced by their limiting values h1 =
τaη exp(−ητa)
1−exp(−ητa)
and h2 =
τ2aη exp(−ητa)
2[1−exp(−ητa)]
.
For uniform patient entry (η → 0) and δ 6= 0, (20) reduces to
h(t) = δ
τa − t
τa
+
1
τa
,
h1 =
1− exp(−δτa)
δτa
,
h2 =
1− (δτa + 1) exp(−δτa)
δ2τa
,
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and π(t) = exp(−δt) if t ≤ τc, π(t) = τ−tτa exp(−δt) if t > τc.
In design 2, when δ = 0, we have E(tgj) = τ−E(egj) and E(t2gj) = [τ−2E(egj)]τ+E(e2gj), where E(egj) = τa/2, E(e2gj) = τ2a/3
if η → 0, and E(egj) = 1−(ητa+1) exp(−ητa)η[1−exp(−ητa)] , E(e2gj) =
2−[η2τ2a+2ητa+2] exp(−ητa)
η2[1−exp(−ητa)]
if η 6= 0. When δ = 0, dg can still be calculated
using the last equality in (19).
If the dropout rate or the dispersion parameter vary by the treatment group, dg, E(tgj) and E(t
2
gj) can be computed by
replacing δg and/or κg by the treatment specific values.
A.2 Back-calculation of κ based on published summary results
Back-calculation of κ based on results from the NB regression
Suppose a historical trial is analyzed using the NB regression. Let firstly assume the event rate for each arm is reported.
Let λˆg be the estimated event rate, and Vˆλg the associated variance for group g. Using (6) and the result in Tang (2015), we
can show that the variance Vˆγg = Vˆλg/λˆ
2
g for γˆg = log(λˆg) is bounded by
1
ngdˆgu
≤ Vˆγg = [
ng∑
j=1
λˆgtgj
1 + κˆλˆgtgj
]−1 ≤ 1
ngdˆ∗gl
, (21)
where t¯g and tmg denote respectively the mean and maximum follow-up time in group g, and
dˆgu =
λˆg t¯g
1 + κˆλˆg t¯g
and dˆ∗gl =
λˆg t¯g
1 + κˆλˆgtmg
.
Inverting (21) yields
ngVˆγg −
1
λˆgtmg
≤ κˆ ≤ ngVˆγg −
1
λˆg t¯g
. (22)
In (22), λˆg t¯g is the expected mean number of events in group g, and it may be replaced by the observed mean number of events
if t¯g is not reported in the literature.
Now suppose the event rate ratio and its variance are reported. The variance Vˆγ01 of log(λˆ1/λˆ0) = γˆ1 − γˆ0 is bounded by
1
n0dˆ0u
+
1
n1dˆ1u
≤ Vˆγ01 ≤
1
n1dˆ∗1l
+
1
n0dˆ∗0l
. (23)
Inverting (23) yields
Vˆγ01 − (n0λˆ0t¯0)−1 − (n1λˆ1 t¯1)−1
tm0/(n0t¯0) + tm1/(n1t¯1)
≤ κˆ ≤ Vˆγ01 − (n0λˆ0 t¯0)
−1 − (n1λˆ1t¯1)−1
n−10 + n
−1
1
. (24)
We illustrate the calculation with an example. Wang et al. (2009) reported the analysis of a two-arm MS trial, in which
n1 = 627 was randomized to the active treatment, and n0 = 315 subjects received placebo. The mean number of events was
1.1 in the placebo arm, and 0.4 in the active arm. The mean follow-up time was 1.80 years for placebo and 1.88 years for
the active treatment. The maximum treatment duration is 2 years. The rate ratio and its 95% CI from the NB regression is
31.3% (25.2−38.9%). Log-transformation of the CI for λ1/λ0 yields the estimate of γˆ1−γˆ0 (95% CI) as −1.162 (−1.378,−0.944),
and its variance is 0.0122. The event rate estimate from the NB regression was not reported for each individual treatment.
We replace λˆg t¯g by the observed mean number of events n¯g, and estimate λˆg using n¯g/t¯g. An application of (24) yields
1.033 ≤ κˆ ≤ 1.113, and this is roughly consistent with the reported MLE κˆ = 0.99. The difference in the estimate of κ arises
possibly due to two main reasons. Firstly, we do not know the MLE of (λˆ0, λˆ1). Secondly, we ignore the fact that the analysis
in Wang et al. (2009) adjusted for some covariates. In general, inclusion of important risk factors in the model reduces the
heterogeneity and κ.
Back-calculation of κ based on results from the quasi-Poisson regression
This method is similar to that described in Zhu and Lakkis (2014), but we correct an error in their formula. In the quasi-
Poisson regression, the event rate estimate is λˆg =
∑ng
j=1 ygj/
∑ng
j=1 tgj by assuming that the event counts follow the Poisson
distribution. The variance of λˆg is firstly derived under the Poisson assumption, and then inflated by a factor of φ to adjust
for potential overdispersion (Wang et al., 2009)
var(λˆg) = φλˆg/(ng t¯g) and var(γˆg) = var(log(λˆg)) = φ/(ngλˆg t¯g).
Therefore, φ can be back-calculated as
φˆ = ngλˆg t¯gvar(γˆg) = ng t¯gvar(λˆg)/λˆg.
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The CI of λˆg is calculated as [exp(γˆg − z1−α/2
√
var(λˆg)), exp(γˆg + z1−α/2
√
var(λˆg))]. If the CI of λˆg is reported, one needs
to log-transform the CI of λˆg to get the CI of γˆg before back-calculating var(γˆg) or var(λˆg). See Zhu and Lakkis (2014) for a
numerical illustration. If the CI of λ1/λ0 is reported, one can derive var(γˆ1 − γˆ0), and then back calculate φ using
φˆ =
var(γˆ1 − γˆ0)
1/(n1λ1 t¯1) + 1/(n0λ0 t¯0)
.
In the quasi-Poisson regression, the estimate of φ is given by
φˆ =
∑
g
∑
j(ygj − µˆgj)2/µˆgj
n− p ,
which is roughly an unbiased estimate of 1+κµ¯, where p is the rank of covariates, and µ¯ =
∑
g
∑
j µgj/n is the expected mean
number of events among all subjects used in the analysis. We can estimate µ¯ by p1λ1 t¯1 + p0λ0t¯0 if there is no other covariate
except the treatment status. An estimate of κ is given by
κˆ = (φˆ− 1)/µ¯. (25)
Zhu and Lakkis (2014) suggested a wrong estimate κˆ = (φˆ− 1)/λ¯, where λ¯ is the pooled event rate in the two arms.
In the MS trial reported by Wang et al. (2009), φˆ = 1.828. The overall mean number of observed events is µ¯ = (1.1 ∗ 315 +
0.4 ∗ 627)/(315 + 627) = 0.634. The use of Zhu-Lakkis formula yields κˆ = 2.436, which is clearly too far from the MLE of κ
from the NB regression. An application of (25) yields κˆ = 1.306. It provides quite a good initial guess about the dispersion κ
given the limited information.
A.3 Explanation of type I error inflation in quasi-Poisson regression
Let consider a simple situation. We assume the same mean follow-up time (t¯1 = t¯2 = t¯) and the same sample size (n1 = n0 = n¯)
in the two arms. Suppose the data follow the NB distribution ygj ∼ NB(γgtgj , κ), and this holds approximately in many
empirical studies (Glynn and Buring, 1996; Wang et al., 2009; Aban et al., 2009). In the quasi-Poisson regression, the event
rate estimate λˆpg =
∑ng
j=1 ygj/
∑ng
j=1 tgj is unbiased for λg. The variance of the log relative risk estimate βˆp = log(λˆp1/λˆp0)
can be derived by the delta method,
vartrue(βˆp) =
n1t¯1 + κγ1
∑
j t
2
1j
n21t¯
2
1γ1
+
n0t¯0 + κγ0
∑
j t
2
0j
n20t¯
2
0γ0
=
1
n1t¯1γ1
+
1
n0t¯0γ0
+ κ[
∑
j t
2
1j
n¯2t¯2
+
∑
j t
2
0j
n¯2t¯2
]. (26)
By the result in Appendix A.2, the variance estimate in the quasi-Poisson regression is given by
varpoi(βˆp) = (1 + κµ)[
1
n1λ1t¯1
+
1
n0λ0 t¯0
] =
1
n1t¯1γ1
+
1
n0t¯0γ0
+ κ
(λ0 + λ1)
2
2n¯λ0λ1
. (27)
Thus
vartrue(βˆp)− varpoi(βˆp) = κ
n¯
[∑
j(t1j − t¯)2
n¯ t¯2
+
∑
j(t0j − t¯)2
n¯ t¯2
− (λ0 − λ1)
2
2λ0λ1
]
≈ κ
n¯
[
2CV2t −
(λ0 − λ1)2
2λ0λ1
]
,
where CVt is the coefficient of variation for tgj , which is assumed to be the same in the two arms. Note that (λ0−λ1)2/(2λ0λ1) =
0 under H0 : λ0 = λ1 in superiority trials, and (λ0−λ1)2/(2λ0λ1) ≈ 0 under H0 in NI and equivalence trials. For example, when
the margin on the rate ratio metric is Mr0 = 1.3 in a NI trial (i.e. λ1/λ0 = 1.3 under H0), we have (λ0−λ1)2/(2λ0λ1) = 0.035.
When the follow-up times vary greatly across patients, the quasi-Poisson approach underestimates the variance of βˆp under
H0, leading to the type I error inflation.
A.4 Technical proofs
Proof of (11): Let λ¯ =
√
λ0λ1. Then λ0 = λ¯ exp(−β/2), λ1 = λ¯ exp(β/2) and λ0 − λ1 = λ¯[exp(−β/2) − exp(β/2)] ≈ −λ¯β.
We can approximate (5) by n˜r = [(p0d˜)
−1 + (p1d˜)
−1]f , and (10) by n˜d = [λ¯
2/(p0d˜) + λ¯
2/(p1d˜)](z1−α/2 + zP )
2/(Md0 + λ¯β)
2,
where d˜ = E[κλ¯/(1 + κλ¯)]. If (11) holds, then nd ≈ n˜d = n˜r ≈ nr.
Proof of (16): The power in (28) satisfies
P + 1 = Φ
( √
n[log(Mru)− β]√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
+Φ
( √
n[β − log(Mrl)]√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
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which is bounded by
2Φ
( √
n∆min√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
≤ P + 1 ≤ 2Φ
( √
n∆max√
(d0p0)−1 + (d1p1)−1
− z1−α/2
)
.
Inverting the above inequalities yields (16).
Online Supplementary Materials
The online supplementary materials contain the SAS macro for calculating the power and sample size for comparing NB rates
based on both the absolute and relative rate difference in superiority, NI and equivalence trials. It allows the dropout rate and
dispersion parameter to vary by treatment group. A R package with similar functions is in development.
SAS MACRO is provided for implementing the power and sample size calculation for comparing NB rates based on both
the absolute and relative rate differences in superiority, NI and equivalence trials. It allows the dropout rate and dispersion
parameter to vary by treatment group. A R package with similar functions is in development.
Below are key equations and notations used in the macro. Let Y ∼ NB(µ, κ) denote the Negative Binomial (NB) distribution
with mean µ, dispersion κ and variance µ + κµ2. Suppose in a clinical trial, n subjects are randomized to the experimental
(g = 1) or control (g = 0) treatment. Let tgj be the follow-up time, and ygj ∼ NB(µgj = λgtgj , κg) the number of observed
events for subject j = 1, . . . , ng in group g.
For the rate ratio metric, we let pg = ng/n, dg = E[λgtgj/(1 + κgλgtgj)],
σ2 =
1
d0p0
+
1
d1p1
, β = log(λ1/λ0), β
∗ = log(Mr0)− β,
∆a = log(Mru)− β,∆b = log(Mrl)− β,∆min = min[∆a,−∆b],∆max = max[∆a,−∆b]
where Mr0 is the NI margin, (Mrl < 1,Mru > 1) is the equivalence margin.
For the absolute rate difference metric, we define
σ2 =
λ20
d0p0
+
λ21
d1p1
, β = λ1 − λ0, β∗ = Md0 − β,
∆a = Mdu − β,∆b = Mdl − β,∆min = min[∆a,−∆b],∆max = max[∆a,−∆b]
where Md0 is the NI margin, (Mdl < 0,Mdu > 0) is the equivalence margin.
The power and sample size formulae for a NI trial are given by
P = Φ
(√
n|β∗|√
σ2
− z1−α/2
)
and n =
(z1−α/2 + zP )
2σ2
β∗2
.
The formulae for a superiority trial can be obtained by setting Mr0 = 1 on the rate ratio metric or Md0 = 0 on the absolute
rate difference metric. The formulae for NI trials are valid if
(1) Mr0 > 1, λ1/λ0 < Mr0: to show that the active rate is not materially higher than the control rate.
(2) Mr0 < 1, λ1/λ0 > Mr0: to show that the active rate is not materially lower than the control rate.
(3) Md0 > 0, λ1 − λ0 < Md0: to show that the active rate is not materially higher than the control rate.
(4) Md0 < 0, λ1 − λ0 > Md0: to show that the active rate is not materially lower than the control rate.
In an equivalence trial, the power is
P = Φ
(√
n∆a√
σ2
− z1−α/2
)
− Φ
(√
n∆b√
σ2
+ z1−α/2
)
= Φ
(√
n∆a√
σ2
− z1−α/2
)
+Φ
(−√n∆b√
σ2
− z1−α/2
)
− 1.
If the sample size is too small, P can be negative, which will be set to P = 0. The sample size is bounded by
(z1−α/2 + z(1+P )/2)
2σ2
∆2max
≤ n ≤ (z1−α/2 + z(1+P )/2)
2σ2
∆2min
.
If ∆min = ∆max, both the lower and upper bounds are equal to the desired sample size. Otherwise the bisection method is
used to calculate the sample size, at which the power is no smaller than the target power. In the equivalence trial, we require
that λ1/λ0 lies within the interval [Mrl,Mru] (rate ratio metric) or that λ1 − λ0 lies within the interval [Mdl,Mdu] (absolute
rate difference metric). That is ∆a > 0, ∆b < 0, and ∆max ≥ ∆min > 0.
Note that dg is bounded by
dgl =
λgE
2(tgj)
E(tgj) + κgλgE(t2gj)
≤ dg ≤ dgu =
λgE(tgj)
1 + κgλgE(tgj)
,
Replacing dg by dgu and dgl in the power and sample size formulae yields the corresponding lower and upper bounds on power
and sample size. We calculate dg, dgu , dgl , E(tgj) and E(t
2
gj) using the formulae in Appendix A.1 of the main paper.
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*** Power & sample size for comparing Negative Binominal rates;
*** in superiority noninferiority & equivalence trials with dropouts;
*** The methods allow the dispersion parameter and dropout rates to
vary by treatment group, and the treatment comparison can be based
on both the absolute and relative rate difference metrics;
*** If you have any comments & suggestions, please send them to
yongqiang_tang@yahoo.com;
*** Reference
1. Tang, Y., 2015. Sample size estimation for negative binomial
regression comparing rates of recurrent events with unequal
follow-up time.
Journal of Biopharmaceutical Statistics 25, 1100-13;
*** 2. Tang Y. 2017, Sample size for comparing negative binomial rates
in noninferiority and equivalence trials with unequal follow-up
time. Journal of Biopharmaceutical Statistics (accepted);
*** 3. Tang, Y., 2017. Negative binomial regression: Sample size with
unequal follow-up times. In: Encyclopedia of Biopharmaceutical
Statistics, Third Edition DOI: 10.1081/E-EBS3-140000049;
*** The estimate in Zhu (2017, Journal of Biopharmaceutical research,
vol. 9, page 107-115) or Zhu-Lakkis (2014, statistics in Medicine,
vol. 33, page 376387) is produced for rate ratio based test if
the diserpsion and dropout rates do not vary with treatment group;
*** Zhu’s estimate is generally close to Tang’s lower size bound;
%macro NBsize(lambda0=1,lambda1=0.8,kappa0=1,kappa1=,tauc=2,taua=2,
droprate0=0.2,droprate1=,p0=0.5,alpha=0.05,power=0.8,ntot=,Mr0=1.3,
Mru=1.3, Mrl=, Md0= 0.262, Mdu=0.262, Mdl=, eta=0, type =SUP,
metric=ratio, design=1);
*** lambda0,lambda1 -- event rates in control and active arms ;
*** kappa0,kappa1--dispersion parameter for the control & active arms;
**if kappa1=., it will be set to kappa1=kappa0 (same in two arms);
*** droprate0, droprate1 --- exponential dropout rate in two arms;
**if droprate1=., it will be set to droprate1=droprate0;
*** Mr0 -- noninferiority (NI) margin on rate ratio;
*** Mru, Mrl --- Equivalence margins on rate ratio;
** If MRl=., it will be set to Mrl=1/Mru;
*** Md0 -- noninferiority (NI) margin on absolute rate difference;
*** Mdu, Mdl --- Equivalence margins on absolute rate difference;
** if Mdl=. , it will be set to Mdl=-Mdu;
*** Metric = RATIO (treatment is compared on the rate ratio metric);
** Metric=DIFF (absolute rate difference treatment effect metric);
*** In design=1, the planned treatment duration is tauc time unit for
all subjects;
*** In design=2, the enrollment period is taua Time Unit. Subject will
be followed for an additional tauc UNIT after the recruitment
period. The total study duration is tau=tauc+taua;
*** In design=2, the entry time distribution is uniform if eta=0,
eta * exp(-eta*t)/[1-exp(-eta *taua)] if eta^=0;
*** Ntot -- total sample size, if Ntot is not missing, nominal power
will be calculated at the given Ntot;
*** Power- target power, if not missing, sample size will be computed;
data _NULL_;
if &droprate1=. then call symput(’droprate1’,&droprate0);
if &kappa1=. then call symput(’kappa1’,&kappa0);
if &mrl=. then call symput(’mrl’,1/&mru);
if &Mdl=. then call symput(’Mdl’,-&Mdu);
run;
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data parametercheck;
length error $200.;
nerror=0;
if (upcase("&metric") in (’RATIO’, ’DIFF’))^=1 then do;
nerror=nerror+1;
error=’Metric should be equal to RATIO or DIFF’;
end;
else if (upcase("&type") in (’SUP’,’NI’,’EQUI’))^=1 then do;
nerror=nerror+1;
error=’Type should be equal to SUP, NI or EQUI’;
end;
else if (&droprate1<0) | (&droprate0 <0) | (&lambda1<=0) |
(&lambda0<=0) | (&kappa0<0) | (&kappa1<0) | (&tauc<=0)
then do;
nerror=nerror+1;
error=’Error: droprate0/droprate1,lambda0/lambda1,kappa0/kappa1,
tauc shall be non-negative or positive’;
end;
else if ("&design" in (’1’,’2’))^=1 then do;
nerror=nerror+1;
error= ’Error: design should be equal to 1 or 2’;
end;
else if ((&power^=.) & (&power<=0)) | (&power>=1) |
((&ntot^=.) & (&ntot<0)) | ((&power=.) & (&ntot=.)) |
((&power>0) & (&ntot>0)) then do;
nerror=nerror+1;
error= ’Error: there should be either 0<power<1, ntot=.
OR ntot>0 & power=.’;
end;
else if &design=2 & &taua<0 then do;
nerror=nerror+1;
error= ’Error: taua must be >0 in design 2’;
end;
else if &p0<0 | &p0>1 then do;
nerror=nerror+1;
error=’Error: p0 the proprotion of subject in control
arm must be between 0 and 1’;
end;
else if index(upcase("&type"), ’SUP’)>0 & &lambda1=&lambda0
then do;
nerror=nerror+1;
Error=’Error: lambda0 & lambda1 should be different in a
superiority trial’;
end;
else if index(upcase("&type"),’EQUI’)>0 & upcase("&metric")=’DIFF’ &
((&Mdu=.) | (&Mdl=.)| (&lambda1-&lambda0>=&Mdu) |
(&lambda1-&lambda0<=&Mdl)) then do;
nerror=nerror+1;
error=’Error: Equivalence DIFF margin must satisfy
Mdl< lambda1-lambda0<Mdu, Mdu^=.’;
end;
else if index(upcase("&type"),’EQUI’)>0 & upcase("&metric")=’RATIO’ &
((&lambda1/&lambda0>=&Mru) | (&lambda1/&lambda0<=&Mrl)) then do;
nerror=nerror+1;
error=’Error: Equivalence RATIO margin must satisfy
Mrl< lambda1/lambda0<Mru, Mru^=.’;
end;
else if index(upcase("&type"),’NI’)>0 & upcase("&metric")=’RATIO’ &
((&MR0=.)| (&Mr0<=0) | (&lambda1/&lambda0=&Mr0)) then do;
nerror=nerror+1;
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error=’Error: NI RATIO Margin must satisfy Mr0>0 & lambda1/lambda0^= Mr0’;
end;
else if index(upcase("&type"),’NI’)>0 & upcase("&metric")=’DIFF’ &
((&Md0=.) | (&lambda1-&lambda0=&Md0)) then do;
nerror=nerror+1;
error=’Error: NI DIFF margin must satisfy MD0^=. and lambda1-lambda0^= Md0’;
end;
call symput(’nerror’, nerror);
run;
%if &nerror>0 %then %do;
proc print data=parametercheck noobs;var error;run;
%end;
%if &nerror<=0 %then %do;
proc iml;
start d0fordesign1(design) global(lambda, kappa, droprate,tauc);
start d0fun(t) global(droprate, lambda, kappa);
vv =exp(- droprate *t) *lambda /((1+kappa*lambda*t)**2);
return(vv);
finish;
if droprate^=0 then do;
c = 0||tauc;
call quad(d0,"d0fun",c);
tbar = (1-exp(-droprate *tauc))/droprate;
t2bar = 2*(1-(droprate *tauc+1)*exp(-droprate*tauc))/(droprate**2);
du = lambda*tbar/(1+kappa*lambda*tbar);
dl = lambda*(tbar**2)/(tbar+kappa *lambda*t2bar);
end;
if droprate =0 then do;
tbar=tauc;
t2bar =tauc**2;
d0= lambda*tauc/(1+kappa*lambda*tauc);
du=d0;
dl=d0;
end;
return (d0||dl||du||tbar||t2bar);
finish;
start d0fordesign2(design) global(lambda, kappa, droprate,eta, taua, tauc);
start d0fun2(t) global(droprate, lambda, kappa, eta, taua,tauc);
vv =exp(- droprate *t) *lambda /((1+kappa*lambda*t)**2);
if t>tauc then do;
if eta^=0 then vv=vv*(1-exp(-eta*(tauc+taua-t)))/(1-exp(-eta*taua));
else if eta=0 then vv=vv* (tauc+taua-t)/taua;
end;
return(vv);
finish;
c = 0||(tauc+taua);
call quad(d0,"d0fun2",c);
if droprate^=0 then do;
if eta^=0 then temp = eta * exp(-eta *taua)/(1-exp(-eta*taua));
else temp= 1/taua;
if droprate=eta then do;
hg1=temp*taua;
hg2=taua**2/2*temp;
end;
else do;
hg1 = (1-exp(-(droprate-eta)*taua))/(droprate-eta)*temp;
hg2=(1-((droprate-eta)*taua+1)*exp(-(droprate-eta)*taua))/((droprate-eta)**2)*temp;
end;
tbar=(1 -exp(-droprate * tauc)*hg1)/droprate;
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t2bar = 2*( 1-((droprate*tauc+1)*hg1+droprate *hg2)*exp(-droprate*tauc))/(droprate**2);
end;
if droprate =0 then do;
if eta=0 then do;
tbar=tauc+taua/2;
t2bar =(tauc+taua)*tauc+taua**2/3;
end;
else do;
eattaua=eta*taua;
Ee = (1-(eattaua+1)*exp(-eattaua))/(1-exp(-eattaua))/eta;
Ee2 = (2- (eattaua**2+2*eattaua+2)*exp(-eattaua))/(1-exp(-eattaua))/(eta**2);
tbar=tauc+taua-Ee;
t2bar=(tauc+taua)**2- 2*Ee*(tauc+taua)+Ee2;
end;
end;
du = lambda*tbar/(1+kappa*lambda*tbar);
dl = lambda*(tbar**2)/(tbar+kappa *lambda*t2bar);
return ((d0||dl||du||tbar||t2bar));
finish;
**** estimate size for equivalence trial using bisection method;
start size_equiv(beta, margl, margu, var, alpha, power,tolerence);
tempu= margu-beta;
templ= -margl+beta;
n_up = (probit(1-&alpha/2)+probit((&power+1)/2))**2*var/ min(tempu**2, templ**2);
if abs(tempu-templ)<0.000000000001 then nnreq=n_up;
else do;
n_low= (probit(1-&alpha/2)+probit(&power))**2*var/max(tempu**2,templ**2);
do while (abs(n_up-n_low)>tolerence);
n_mid=(n_low+n_up)/2;
pow_up = probnorm(sqrt(n_mid/var)*(margu -beta) - probit(1-&alpha/2))-
probnorm(sqrt(n_mid/var)*(margl-beta) + probit(1-&alpha/2));
if pow_up > power then n_up = n_mid;
else n_low= n_mid;
end;
nnreq=n_mid;
end;
return(nnreq);
finish;
start varnull(type, Mr0, p0, p1, lambda0,lambda1, kappa, ET);
if upcase(type)="SUP" then do;
r0tilde =p0*lambda0+p1*lambda1;
r1tilde =r0tilde ;
end;
else do;
theta=p1/p0;
a=-kappa * et * Mr0*(1+theta);
b=kappa*et*(lambda0*Mr0+theta* lambda1) -(1+theta* Mr0);
c=lambda0+theta* lambda1;
if kappa^=0 then r0tilde = (-b-sqrt(b*b-4*a*c))/(2*a);
if kappa=0 then r0tilde=(lambda0+theta*lambda1)/(1+theta*Mr0);
r1tilde=r0tilde* Mr0;
end;
v0=kappa/(p0*p1) + (1/(p0*r0tilde)+1/(p1*r1tilde))/et;
return (v0);
finish;
if &design=1 then do;
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*** the planned duration is tauc for all subjects, exponential dropout rate;
lambda=&lambda0; kappa=&kappa0;droprate=&droprate0;tauc=&tauc;
par0= d0fordesign1(1);
droprate=&droprate1; kappa=&kappa1; lambda=&lambda1;
par1= d0fordesign1(1);
end;
if &design=2 then do;
*** the planned duration is tauc for all subjects, exponential dropout rate;
lambda=&lambda0; kappa=&kappa0;droprate=&droprate0;tauc=&tauc;taua=&taua;
eta=&eta;
par0= d0fordesign2(2);
droprate=&droprate1; kappa=&kappa1; lambda=&lambda1;
par1= d0fordesign2(2);
end;
p0=&p0; p1=1-p0;
print ’d0 dl du E(t) E(t*t) in control arm’ par0;
print ’d0 dl du E(t) E(t*t) in active arm’ par1;
if upcase("&metric") = ’RATIO’ then do;
vard0 = 1/(par0[1]*p0)+1/(par1[1]*p1);
vardl = 1/(par0[2]*p0)+1/(par1[2]*p1);
vardu = 1/(par0[3]*p0)+1/(par1[3]*p1);
beta=log((&lambda1)/(&lambda0));
if upcase("&type")=’NI’ then beta = log(&Mr0)-beta;
else if upcase("&type")=’EQUI’ then do;
margl=log(&mrl); margu=log(&mru);
end;
end;
else do;
vard0 = (&lambda0)**2/(par0[1]*p0)+(&lambda1)**2/(par1[1]*p1);
vardl = (&lambda0)**2/(par0[2]*p0)+(&lambda1)**2/(par1[2]*p1);
vardu =(&lambda0)**2/(par0[3]*p0)+(&lambda1)**2/(par1[3]*p1);
beta=&lambda1-&lambda0;
if upcase("&type")=’NI’ then beta = &MD0 - beta;
else if upcase("&type")=’EQUI’ then do;
margl=&Mdl; margu=&Mdu;
end;
end;
if (upcase("&type")=’NI’ | upcase("&type")=’SUP’) then do;
if &power>0 then do;
temp = (probit(1-&alpha/2)+probit(&power))**2/(beta**2);
nreq_raw = temp*vard0; nreq=ceil(nreq_raw);
nlow = ceil(temp *vardu);
nup = ceil(temp*vardl);
print ’The required size (before rounding) is’ nreq_raw, ’which is rounded up to’ nreq;
print ’The low and upper sample size bounds are’ nlow nup;
power_nominal = probnorm( sqrt(nreq/vard0)*abs(beta)-probit(1-&alpha/2));
print ’The nominal power is’ power_nominal ’at the sample size’ nreq;
if (&droprate1=&droprate0) & (&kappa1=&kappa0) & upcase("&metric") =’RATIO’ then do;
v0= varnull("&type", &Mr0, p0, p1, &lambda0,&lambda1, &kappa0, par0[4]);
nzl = probit(&alpha/2)*sqrt(v0)+ probit(1-&power)*sqrt(vardu);
nzl=ceil(nzl**2/beta/beta);
print ’Zhu (2017) or Zhu-Lakkis (2014) estimate using variance under null via MLE’ nzl;
print ’It is generally close to Tang lower size bound.’;
end;
end;
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if &ntot>0 then do;
power_nominal = probnorm( sqrt(&ntot/vard0)*abs(beta)-probit(1-&alpha/2));
print ’The nominal power is’ power_nominal ’at the sample size’ (&ntot);
end;
end;
if upcase("&type")=’EQUI’ then do;
if &power>0 then do;
nreq_raw = size_equiv(beta, margl, margu, vard0, &alpha, &power,0.00001);
nreq=ceil(nreq_raw);
power_nominal = probnorm(sqrt(nreq/vard0)*(margu-beta) - probit(1-&alpha/2))-
probnorm(sqrt(nreq/vard0)*(margl-beta) + probit(1-&alpha/2));
nlow = size_equiv(beta, margl, margu, vardu, &alpha, &power,0.00001);
nup = size_equiv(beta, margl, margu, vardl, &alpha, &power,0.00001);
nlow=ceil(nlow);
nup=ceil(nup);
print ’The required size (before rounding) is’ nreq_raw,
’which is rounded up to’ nreq ’at margin’ (&Mrl) (&Mru);
print ’The nominal power is’ power_nominal ’at the sample size’ nreq;
print ’The low and upper sample size bounds are’ nlow nup;
if (&droprate1 = &droprate0) & (&kappa1=&kappa0) & upcase("&metric")=’RATIO’ then do;
v0plus= varnull("&type", &Mru, p0, p1, &lambda0,&lambda1, &kappa0, par0[4]);
v0minus=varnull("&type", &Mrl, p0, p1, &lambda0,&lambda1, &kappa0, par0[4]);
nzl=probit(&alpha/2)*sqrt(v0plus)+ probit(1-&power)*sqrt(vardu);
nzl=ceil(nzl**2/((log(&Mru*&lambda0/&lambda1))**2));
prob=0;
do while (prob<&power);
nzl=nzl+1;
prob1= sqrt(nzl)*abs(log(&mru*&lambda1/&lambda0)) -probit(1-&alpha/2)*sqrt(v0minus);
prob2 = sqrt(nzl)*abs(log(&mrl*&lambda1/&lambda0)) - probit(1-&alpha/2)*sqrt(v0plus);
prob=probnorm(prob1/sqrt(vardu))+probnorm(prob2/sqrt(vardu))-1;
end;
print ’Zhu (2017) estimate using variance under null via MLE’ nzl;
print ’It is generally close to Tang lower size bound.’;
end;
end;
if &ntot>0 then do;
power_nominal = probnorm(sqrt(&ntot/vard0)*(margu-beta) - probit(1-&alpha/2))-
probnorm(sqrt(&ntot/vard0)*(margl-beta) + probit(1-&alpha/2));
if power_nominal<0 then power_nominal =0;
print ’The nominal power is’ power_nominal ’at the sample size’ (&ntot);
end;
end;
quit;
%end;
%mend;
**** example 1: superiority trial, equal dropout and dispersion, to calculate sample size;
%NBsize(lambda0=0.6, lambda1=0.3, kappa0=1, kappa1=., tauc=2, taua=2, droprate0=0.178,
droprate1=., p0=0.5, alpha=0.05, power=0.8, ntot=., Mr0=1.2, Mru=1.3, Mrl=., Md0= 0.1613,
Mdu=0.1613, Mdl=., eta=0, type =sup, metric=ratio, design=1);
**** example 2: noninferiority trial, equal dropout and dispersion, to calculate sample size;
%NBsize(lambda0=0.6, lambda1=0.36, kappa0=1, kappa1=., tauc=2, taua=2, droprate0=0.3,
droprate1=., p0=0.5, alpha=0.05, power=0.8, ntot=., Mr0=1.2, Mru=1.3, Mrl=., Md0= 0.1613,
Mdu=0.1613, Mdl=., eta=0, type =ni, metric=ratio, design=2);
**** example 3: noninferiority trial, dispersion vary by treatment, rate ratio test;
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%NBsize(lambda0=0.6, lambda1=0.48, kappa0=2, kappa1=1, tauc=2, taua=2, droprate0=0.1438,
droprate1=., p0=0.5, alpha=0.05, power=0.8, ntot=., Mr0=1.3, Mru=1.3, Mrl=., Md0= 0.1613,
Mdu=0.1613, Mdl=.,eta=0, type =ni, metric=ratio, design=1);
**** example 4: noninferiority trial, dispersion vary by treatment, rate difference metric;
%NBsize(lambda0=0.6, lambda1=0.48, kappa0=2, kappa1=1, tauc=2, taua=2, droprate0=0.1438,
droprate1=., p0=0.5, alpha=0.05, power=0.8, ntot=., Mr0=1.3, Mru=1.3, Mrl=., Md0= 0.1408,
Mdu=0.1613, Mdl=., eta=0, type =ni, metric=diff, design=1);
**** example 5: equivalence trial, equal dropout and dispersion, rate ratio metric;
%NBsize(lambda0=0.6, lambda1=0.63, kappa0=1, kappa1=1, tauc=2, taua=2, droprate0=0.2,
droprate1=., p0=0.5,alpha=0.05, power=0.8, ntot=., Mr0=1.3, Mru=1.3, Mrl=., Md0= 0.1408,
Mdu=0.1613, Mdl=.,eta=0, type =equi, metric=ratio, design=2);
**** example 6: equivalence trial, equal dropout and dispersion, to calculate power;
%NBsize(lambda0=0.6, lambda1=0.63, kappa0=1, kappa1=1, tauc=2, taua=2, droprate0=0.2,
droprate1=., p0=0.5, alpha=0.05, power=., ntot=1000, Mr0=1.3, Mru=1.3, Mrl=., Md0= 0.1408,
Mdu=0.1613, Mdl=., eta=0, type =equi, metric=ratio, design=2);
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test based on rate ratio test based on rate difference
type I error (%) type I error (%)
λ0 exp(β) κ Mr0 nr NB Poisson Md0 nd NB Poisson
0.6 0.65 1.0 1.2 192 2.61 2.87 0.0882 198 2.65 2.95
0.6 0.80 1.0 1.2 412 2.49 2.79 0.0978 416 2.59 2.92
0.6 0.95 1.0 1.2 1185 2.47 2.70 0.1066 1186 2.53 2.82
0.6 1.00 1.0 1.2 1921 2.46 2.81 0.1094 1921 2.73 3.05
0.6 1.05 1.0 1.2 3540 2.37 2.62 0.1121 3543 2.54 2.83
0.6 0.65 1.0 1.3 150 2.80 3.05 0.1269 155 2.97 3.36
0.6 0.80 1.0 1.3 288 2.66 3.03 0.1408 291 2.70 3.08
0.6 0.95 1.0 1.3 658 2.48 2.76 0.1534 658 2.83 3.09
0.6 1.00 1.0 1.3 928 2.69 2.98 0.1574 928 2.68 3.00
0.6 1.05 1.0 1.3 1384 2.48 2.77 0.1613 1385 2.55 2.91
0.9 0.65 1.5 1.2 202 2.55 2.98 0.1323 212 2.70 3.32
0.9 0.80 1.5 1.2 442 2.63 3.08 0.1468 449 2.61 3.04
0.9 0.95 1.5 1.2 1294 2.51 2.94 0.1599 1295 2.64 3.04
0.9 1.00 1.5 1.2 2107 2.46 2.88 0.1641 2107 2.54 2.89
0.9 1.05 1.5 1.2 3900 2.41 2.87 0.1681 3904 2.49 2.92
0.9 0.65 1.5 1.3 158 2.75 3.22 0.1904 166 2.78 3.39
0.9 0.80 1.5 1.3 309 2.58 3.00 0.2112 313 2.79 3.28
0.9 0.95 1.5 1.3 718 2.68 3.12 0.2301 719 2.80 3.28
0.9 1.00 1.5 1.3 1018 2.48 2.80 0.2361 1018 2.84 3.26
0.9 1.05 1.5 1.3 1525 2.60 3.00 0.2420 1526 2.78 3.14
Table 1: Empirical estimate of the one-sided type I error at the nominal level of 2.5% based on 10000 simulated NI trials for
design 1: a) τc = 2, and the overall dropout rate is 25% (δ = 0.1438); b) exp(β) is used only in the sample size calculation; c)
the data are simulated under the assumption that λ1 = λ0Mr0 for the test based on the rate ratio metric, and λ1 = λ0 +Md0
for the test based on the rate difference metric.
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rate ratio based test rate difference based test
type I error (%) type I error (%)
λ0 exp(β) κ Mr0 nr NB Poisson Md0 nd NB Poisson
0.6 0.65 1.0 1.2 176 2.81 3.59 0.0882 183 2.72 3.55
0.6 0.80 1.0 1.2 381 2.52 3.40 0.0978 385 2.60 3.39
0.6 0.95 1.0 1.2 1102 2.43 3.25 0.1066 1103 2.61 3.48
0.6 1.00 1.0 1.2 1789 2.61 3.44 0.1094 1789 2.60 3.50
0.6 1.05 1.0 1.2 3302 2.50 3.32 0.1121 3304 2.47 3.30
0.6 0.65 1.0 1.3 138 2.81 3.68 0.1269 143 2.86 3.69
0.6 0.80 1.0 1.3 266 2.72 3.50 0.1408 269 2.85 3.81
0.6 0.95 1.0 1.3 611 2.62 3.35 0.1534 612 2.62 3.43
0.6 1.00 1.0 1.3 864 2.49 3.36 0.1574 864 2.64 3.49
0.6 1.05 1.0 1.3 1291 2.37 3.17 0.1613 1292 2.64 3.38
0.9 0.65 1.5 1.2 194 2.58 3.76 0.1323 204 2.70 3.95
0.9 0.80 1.5 1.2 427 2.53 3.70 0.1468 434 2.59 3.67
0.9 0.95 1.5 1.2 1255 2.42 3.59 0.1599 1256 2.53 3.66
0.9 1.00 1.5 1.2 2045 2.36 3.59 0.1641 2045 2.49 3.55
0.9 1.05 1.5 1.2 3789 2.40 3.35 0.1681 3793 2.63 3.66
0.9 0.65 1.5 1.3 152 2.78 3.92 0.1904 160 2.85 4.14
0.9 0.80 1.5 1.3 298 2.61 3.69 0.2112 303 2.74 4.08
0.9 0.95 1.5 1.3 696 2.65 3.79 0.2301 697 2.97 3.93
0.9 1.00 1.5 1.3 988 2.48 3.57 0.2361 988 2.69 3.91
0.9 1.05 1.5 1.3 1481 2.57 3.57 0.2420 1483 2.61 3.74
Table 2: Empirical estimate of the one-sided type I error at the nominal level of 2.5% based on 10000 simulated NI trials for
design 2: a) τa = τc = 2, and the loss-to-follow-up is exponentially distributed with mean 5 years (δ = 0.2); b) exp(β) is used
only in the sample size calculation; c) the data are simulated under the assumption that λ1 = λ0Mr0 for the test based on the
rate ratio metric, and λ1 = λ0 +Md0 for the test based on the rate difference metric.
rate ratio based test rate difference based test
total sample size SIM (%) total sample size SIM (%) at
λ0 exp(β) κ Mr0 nzr nrl nr nru at nr Md0 ndl nd ndu nd nr
0.6 0.65 1.0 1.2 182 186 192 194 80.47 0.0882 191 198 200 81.45 80.29
0.6 0.80 1.0 1.2 396 397 412 416 80.50 0.0978 401 416 420 80.29 80.65
0.6 0.95 1.0 1.2 1143 1142 1185 1197 79.25 0.1066 1143 1186 1198 80.73 79.53
0.6 1.00 1.0 1.2 1853 1851 1921 1941 79.30 0.1094 1851 1921 1941 79.38 79.38
0.6 1.05 1.0 1.2 3415 3410 3540 3578 79.77 0.1121 3412 3543 3580 79.82 79.61
0.6 0.65 1.0 1.3 143 145 150 152 80.66 0.1269 150 155 157 81.68 80.78
0.6 0.80 1.0 1.3 276 277 288 290 80.55 0.1408 280 291 293 81.22 80.83
0.6 0.95 1.0 1.3 635 634 658 664 80.49 0.1534 634 658 665 80.73 80.73
0.6 1.00 1.0 1.3 897 894 928 938 79.65 0.1574 894 928 938 79.74 79.74
0.6 1.05 1.0 1.3 1337 1333 1384 1399 80.55 0.1613 1334 1385 1400 79.94 80.64
0.9 0.65 1.5 1.2 191 194 202 206 81.41 0.1323 203 212 216 82.18 81.23
0.9 0.80 1.5 1.2 423 424 442 452 80.03 0.1468 430 449 458 81.56 80.09
0.9 0.95 1.5 1.2 1241 1241 1294 1323 79.71 0.1599 1242 1295 1325 80.07 79.77
0.9 1.00 1.5 1.2 2022 2021 2107 2156 79.83 0.1641 2021 2107 2156 79.81 79.81
0.9 1.05 1.5 1.2 3743 3740 3900 3993 80.24 0.1681 3744 3904 3997 79.62 80.12
0.9 0.65 1.5 1.3 149 152 158 161 80.84 0.1904 159 166 169 81.82 80.66
0.9 0.80 1.5 1.3 295 296 309 315 80.78 0.2112 301 313 320 81.25 80.56
0.9 0.95 1.5 1.3 689 689 718 734 80.37 0.2301 689 719 735 79.94 80.49
0.9 1.00 1.5 1.3 977 976 1018 1042 79.80 0.2361 976 1018 1042 79.95 79.95
0.9 1.05 1.5 1.3 1464 1462 1525 1561 80.15 0.2420 1464 1526 1563 79.90 80.45
Table 3: Estimated sample size at the nominal 80% power and simulated power (SIM) at the specified sample size based
on 10000 NI trials for design 1: a) τc = 2, and the overall dropout rate is 25% (δ = 0.1438); b) In the data simulation,
λ1 = λ0 exp(β) for both tests based on relative and absolute rate difference metrics.
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rate ratio based test rate difference based test
total sample size SIM (%) total sample size SIM (%) at
λ0 exp(β) κ Mr0 nzr nrl nr nru at nr Md0 ndl nd ndu nd nr
0.6 0.65 1.0 1.2 160 163 176 182 80.47 0.0882 169 183 190 81.86 80.18
0.6 0.80 1.0 1.2 350 351 381 396 79.66 0.0978 355 385 401 80.64 79.54
0.6 0.95 1.0 1.2 1016 1016 1102 1149 80.81 0.1066 1016 1103 1150 80.06 80.80
0.6 1.00 1.0 1.2 1650 1648 1789 1868 79.97 0.1094 1648 1789 1868 79.74 79.74
0.6 1.05 1.0 1.2 3045 3042 3302 3450 79.78 0.1121 3044 3304 3453 80.21 79.44
0.6 0.65 1.0 1.3 125 128 138 143 81.15 0.1269 133 143 149 81.98 81.02
0.6 0.80 1.0 1.3 244 245 266 276 79.93 0.1408 248 269 280 81.12 80.27
0.6 0.95 1.0 1.3 564 564 611 638 79.94 0.1534 564 612 638 79.85 80.04
0.6 1.00 1.0 1.3 798 796 864 902 80.00 0.1574 796 864 902 79.75 79.75
0.6 1.05 1.0 1.3 1192 1189 1291 1349 81.22 0.1613 1190 1292 1350 80.13 80.94
0.9 0.65 1.5 1.2 176 178 194 208 79.88 0.1323 188 204 220 82.48 79.66
0.9 0.80 1.5 1.2 392 394 427 460 80.35 0.1468 400 434 468 80.64 80.30
0.9 0.95 1.5 1.2 1157 1157 1255 1357 79.86 0.1599 1158 1256 1358 80.38 80.18
0.9 1.00 1.5 1.2 1887 1886 2045 2215 80.10 0.1641 1886 2045 2215 80.01 80.01
0.9 1.05 1.5 1.2 3497 3495 3789 4108 80.86 0.1681 3499 3793 4112 80.33 80.74
0.9 0.65 1.5 1.3 138 140 152 162 80.23 0.1904 148 160 172 82.24 80.12
0.9 0.80 1.5 1.3 274 275 298 321 80.23 0.2112 279 303 327 80.77 80.19
0.9 0.95 1.5 1.3 642 642 696 753 80.05 0.2301 642 697 754 80.02 80.09
0.9 1.00 1.5 1.3 912 911 988 1070 80.23 0.2361 911 988 1070 80.18 80.18
0.9 1.05 1.5 1.3 1368 1367 1481 1606 80.13 0.2420 1368 1483 1608 79.63 79.94
Table 4: Estimated sample size at the nominal 80% power and simulated power (SIM) at the specified sample size based on
10000 NI trials for design 2: a) τa = τc = 2, and the loss-to-follow-up is exponentially distributed with mean 5 years (δ = 0.2);
b) In the data simulation, λ1 = λ0 exp(β) for both tests based on relative and absolute rate difference metrics.
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rate ratio based test rate difference based test
total sample size SIM (%) total sample size SIM (%) at
λ0 κ0 λ1 κ1 Mr0 nrl nr nru at nr Md0 ndl nd ndu nr nd
0.6 2.0 0.48 1.0 1.3 344 358 363 79.48 0.1408 363 378 384 79.66 82.19
0.6 1.0 0.48 2.0 1.3 344 358 363 80.95 0.1408 333 347 351 80.83 79.70
0.6 2.0 0.48 0.5 1.3 311 322 327 79.34 0.1408 337 349 355 79.38 82.64
0.6 0.5 0.48 2.0 1.3 311 322 327 80.62 0.1408 292 302 306 80.44 78.67
1.0 2.0 0.80 1.0 1.3 286 298 306 79.71 0.2347 306 319 327 79.85 82.46
1.0 1.0 0.80 2.0 1.3 286 299 306 80.62 0.2347 276 288 294 80.72 79.00
1.0 2.0 0.80 0.5 1.3 253 263 269 78.69 0.2347 279 290 298 79.18 83.69
1.0 0.5 0.80 2.0 1.3 253 263 269 81.22 0.2347 234 244 249 81.03 78.19
0.6 2.0 0.54 1.0 1.3 584 607 617 79.36 0.1493 598 622 632 80.16 81.28
0.6 1.0 0.54 2.0 1.3 584 608 617 80.31 0.1493 573 597 606 80.13 79.29
0.6 2.0 0.54 0.5 1.3 526 545 553 78.85 0.1493 546 566 575 80.31 81.64
0.6 0.5 0.54 2.0 1.3 526 546 553 80.78 0.1493 509 528 535 80.02 78.71
1.0 2.0 0.90 1.0 1.3 490 510 523 79.55 0.2489 504 525 538 80.27 82.04
1.0 1.0 0.90 2.0 1.3 490 510 523 80.83 0.2489 479 499 512 80.35 79.26
1.0 2.0 0.90 0.5 1.3 432 449 459 78.74 0.2489 452 469 481 80.12 82.79
1.0 0.5 0.90 2.0 1.3 432 449 459 81.04 0.2489 415 431 441 80.04 78.66
0.6 2.0 0.60 1.0 1.3 1122 1168 1187 80.13 0.1574 1122 1168 1187 81.40 81.40
0.6 1.0 0.60 2.0 1.3 1122 1168 1187 80.16 0.1574 1122 1168 1187 79.13 79.13
0.6 2.0 0.60 0.5 1.3 1008 1046 1063 78.82 0.1574 1008 1046 1063 80.82 80.82
0.6 0.5 0.60 2.0 1.3 1008 1046 1063 80.41 0.1574 1008 1046 1063 78.60 78.60
1.0 2.0 1.00 1.0 1.3 947 987 1012 80.23 0.2624 947 987 1012 81.20 81.20
1.0 1.0 1.00 2.0 1.3 947 987 1012 80.24 0.2624 947 987 1012 78.95 78.95
1.0 2.0 1.00 0.5 1.3 833 866 888 79.06 0.2624 833 866 888 81.67 81.67
1.0 0.5 1.00 2.0 1.3 833 866 888 80.92 0.2624 833 866 888 78.82 78.82
Table 5: Estimated sample size at the nominal 80% power and simulated power (SIM) at the specified sample size based on
10000 NI trials for design 1 when the dispersion parameter varies by treatment groups: a) τc = 2, and the overall dropout rate
is 25% (δ = 0.1438).
rate ratio based test rate difference based test
total sample size SIM (%) total sample size SIM (%)
λ0 exp(β) κ nzr
(a) nrl nr nru at nr ndl nd ndu at nd
Design I: τc = 2, overall dropout rate 25% (δ = 0.1438)
0.6 1.00 1.0 1200 1197 1242 1255 79.83 1197 1242 1255 80.12
0.6 1.05 1.0 1386 1382 1435 1451 79.92 1383 1436 1452 80.07
0.9 1.00 1.5 1308 1307 1363 1394 79.75 1307 1363 1394 79.74
0.9 1.05 1.5 1518 1516 1581 1619 80.17 1518 1583 1620 80.10
Design II: τa = τc = 2, exponential dropout rate δ = 0.2
0.6 1.00 1.0 1068 1066 1157 1208 80.28 1066 1157 1208 80.17
0.6 1.05 1.0 1236 1233 1339 1399 79.75 1234 1340 1400 80.41
0.9 1.00 1.5 1190 1189 1288 1402 79.50 1189 1288 1402 79.28
0.9 1.05 1.5 1418 1417 1536 1666 79.94 1418 1538 1667 80.03
Table 6: Estimated sample size at the nominal 80% power and simulated power (SIM) at the specified sample size based on
10000 equivalence trials: a) nzr is estimated using method 3 in Section 4 of Zhu (2017); b) In the data simulation, λ1 = λ0 exp(β)
for both tests based on relative and absolute rate difference metrics; c) The margin is Mru = 1/Mrl = 1.3 on the rate ratio
metric and Mdu = −Mdl = exp(β/2)λ0 log(Mru) on the absolute rate difference metric; d) the lower and upper size bounds
are obtained by numerically inverting the power bounds.
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